Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in APOL1-Associated Nephropathy
NCT02006849Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2014
- Primary completion
- Jan 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of repository corticotropin injection in APOL1-associated nephropathy (AMKD) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Change in proteinuria with H.C. Acthar gel at 1 year and Change in eGFR with H.C. Acthar gel at 1 year. Planned start Jan 2014; status: withdrawn.
02
Drugs
repository corticotropin injection
03
Conditions
APOL1-associated nephropathy (AMKD)
Beyond the preview
Go deeper on NCT02006849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02006849.